- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00438828
Dexamethasone for the Prophylaxis of Pain Flare Study
17. november 2014 opdateret af: Dr. Edward Chow, Sunnybrook Health Sciences Centre
Dexamethasone for the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases
Radiation treatment is often recommended as a safe and quick treatment that gives most people good relief from bone pain within a couple of weeks.
However, some people can experience a short episode of increased pain (called a 'flare') a day or two after radiation treatment, that lasts about a day.
The purpose of this sturdy is to find out if a medication called dexamethasone can help prevent pain flare as a result of radiation therapy.
Studieoversigt
Detaljeret beskrivelse
Of all people diagnosed with cancer, 25% will have their cancer come back and spread to the bones.
This often results in significant pain and suffering.
Radiation treatment is often recommended as a safe and quick treatment that gives most people good relief from bone pain within a couple of weeks.
However, some people can experience a short episode of increased pain called a flare a day or two after radiation treatment that lasts about a day.
Studies suggest that around a third of all people who receive radiation treatment to help pain from cancer in the bones will have a pain flare.
This study is being done because it would be helpful to prevent extra bone pain from happening to people after they receive radiation treatments.
The purpose of this study is to find out if a medication called dexamethasone can help prevent pain flare as a result of radiation therapy.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
61
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Documented bone metastases by radiological imaging
- Patients at least 18 years of age
- Written consent
- KPS ≥ 40
- Baseline worst pain at the planned radiated bony metastatic site ≥ 2
- Patient able to inform the pain score at the planned radiated bony metastatic site
Exclusion Criteria:
- Concurrent use of any corticosteroid medication other than topical or inhaled preparations
- Medical contraindications to corticosteroids such as diabetes mellitus, uncontrolled hypertension or active peptic ulcer
- Pathological fracture of the irradiated extremity
- Spinal cord compression
- Language barrier
- Immediate change in regular analgesic medication. If the oncologist thinks the patient is not receiving adequate analgesic, we recommend the oncologist to increase the analgesic first to stabilize ot lessen the pain before recruiting the patient to this study
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dexamethasone
8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
|
8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Complete control of pain flare on days 1-5 after the completion of radiation treatment.
Tidsramme: Days 1-5
|
Days 1-5
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Complete control of pain flare from Day 6-10 after the completion of radiation treatment.
Tidsramme: Days 6-10
|
Days 6-10
|
|
Functional interference especially mood and sleep in Brief Pain Inventory will be monitored.
Tidsramme: Days 0, 1-10, and 6-weeks from baseline assessment
|
Days 0, 1-10, and 6-weeks from baseline assessment
|
|
Quality of life outcomes
Tidsramme: Baseline and 6-weeks following treatment
|
Baseline and 6-weeks following treatment
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Studiestol: Edward Chow, MBBS PhD, edward.chow@sunnybrook.ca
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. februar 2007
Primær færdiggørelse (Faktiske)
1. juli 2011
Studieafslutning (Faktiske)
1. juli 2011
Datoer for studieregistrering
Først indsendt
20. februar 2007
Først indsendt, der opfyldte QC-kriterier
20. februar 2007
Først opslået (Skøn)
22. februar 2007
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
19. november 2014
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
17. november 2014
Sidst verificeret
1. november 2014
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Autonome agenter
- Agenter fra det perifere nervesystem
- Anti-inflammatoriske midler
- Antineoplastiske midler
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Dexamethason
Andre undersøgelses-id-numre
- SP-14-0055
- Sunnybrook REB# 057-2008 (Anden identifikator: Sunnybrook Health Sciences Centre)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med dexamethasone
-
TheiaNova Ltd.Tilmelding efter invitation
-
Woman'sRekrutteringOral mucositis på grund af kemoterapiForenede Stater
-
Semnur Pharmaceuticals, Inc.Cromos Pharma LLC; SyngeneIkke rekrutterer endnuLumbosakral radikulær smerte
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; Ningbo Medical Center Lihuili Hospital; Jinhua People... og andre samarbejdspartnereRekrutteringInflammatorisk tarmsygdom (IBD) | UC - Colitis ulcerosa | CD - Crohns sygdomKina
-
Poznan University of Medical SciencesRekrutteringHåndskader og lidelser | HåndledsforstuvningPolen
-
Poznan University of Medical SciencesIkke rekrutterer endnu
-
Second Affiliated Hospital, School of Medicine,...RekrutteringKvalme og opkastning forårsaget af Trastuzumab DeruxtecanKina
-
Second Affiliated Hospital, School of Medicine,...RekrutteringKvalme og Opkastning forårsaget af KemoterapiKina
-
Southeast University, ChinaIkke rekrutterer endnuAkut Respiratory Distress Syndrome (ARDS)Kina
-
Valerie ZaphiratosUniversité de MontréalAfsluttetGraviditet | Dexamethason | Kejsersnit leveringCanada